Informations générales (source: ClinicalTrials.gov)
A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
Interventional
Phase 2/Phase 3
Mirati Therapeutics Inc. (Voir sur ClinicalTrials)
décembre 2020
octobre 2029
02 février 2026
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849
monotherapy and in combination with pembrolizumab in cohorts of patients with advanced
NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line
treatment.
The Phase 3 portion of the study compares the efficacy of adagrasib in combination with
pembrolizumab versus pembrolizumab in patients with unresectable, locally advanced or
metastatic squamous or nonsquamous NSCLC with KRAS G12C mutation and PD-L1 TPS >=50% and
who are candidates for first line treatment.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CHI DE CRETEIL | Christos CHOUAID | 08/01/2026 14:50:03 | Contacter | ||
Critères
Tous
- Phase 2: Histologically confirmed diagnosis of unresectable or metastatic NSCLC with
KRAS G12C mutation and any PD-L1 TPS
- Phase 3: Histologically confirmed diagnosis of unresectable or metastatic squamous
or nonsquamous NSCLC with KRAS G12C mutation and PD-L1 TPS >=50%
- Phase 3: Presence of evaluable or measurable disease per RECIST
- Phase 3: CNS Inclusion - Based on screening brain imaging, patients must have one of
the following:
1. No evidence of brain metastases
2. Untreated brain metastases not needing immediate local therapy
3. Previously treated brain metastases not needing immediate local therapy
Exclusion Criteria:
- Phase 2 and Phase 3: Prior systemic treatment for locally advanced or metastatic
NSCLC including chemotherapy, immune checkpoint inhibitor therapy, or a therapy
targeting KRAS G12C mutation (e.g., AMG 510).
- Phase 2: Active brain metastases
- Phase 3: Patients with known central nervous system (CNS) lesions must not have any
of the following:
1. Any untreated brain lesions > 1.0 cm in size
2. Any brainstem lesions
3. Ongoing use of systemic corticosteroids for control of symptoms of brain
lesions at a total daily dose of > 10 mg of prednisone (or equivalent) prior to
randomization.
4. Have poorly controlled (> 1/week) generalized or complex partial seizures, or
manifest neurologic progression due to brain lesions notwithstanding
CNS-directed therapy
- Phase 3: Radiation to the lung > 30 Gy within 6 months prior to the first dose of
study treatment